These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 26806040)
1. Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors. Qi L; Guo Y; Zhang P; Cao X; Luan Y Curr Drug Metab; 2016; 17(2):118-28. PubMed ID: 26806040 [TBL] [Abstract][Full Text] [Related]
2. Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Tsai DE; Luger SM; Kemner A; Swider C; Goradia A; Tomczak E; DiPatri D; Bagg A; Nowell P; Loren AW; Perl A; Schuster S; Thompson JE; Porter D; Andreadis C; Stadtmauer EA; Goldsteini S; Ghalie R; Carroll M Cancer Biol Ther; 2007 Jan; 6(1):18-21. PubMed ID: 17204865 [TBL] [Abstract][Full Text] [Related]
3. Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. DiNardo CD; Ky B; Vogl DT; Forfia P; Loren A; Luger S; Mato A; Tsai DE Med Oncol; 2008; 25(3):299-302. PubMed ID: 18181037 [TBL] [Abstract][Full Text] [Related]
9. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Yen WC; Lamph WW Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282 [TBL] [Abstract][Full Text] [Related]
10. The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats. Nowak B; Matuszewska A; Filipiak J; Nikodem A; Merwid-Ląd A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A Adv Med Sci; 2016 Mar; 61(1):85-9. PubMed ID: 26569440 [TBL] [Abstract][Full Text] [Related]
11. Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene). Furmick JK; Kaneko I; Walsh AN; Yang J; Bhogal JS; Gray GM; Baso JC; Browder DO; Prentice JL; Montano LA; Huynh CC; Marcus LM; Tsosie DG; Kwon JS; Quezada A; Reyes NM; Lemming B; Saini P; van der Vaart A; Groy TL; Marshall PA; Jurutka PW; Wagner CE ChemMedChem; 2012 Sep; 7(9):1551-66. PubMed ID: 22927238 [TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas. Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197 [TBL] [Abstract][Full Text] [Related]
13. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN. Wagner CE; Jurutka PW Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392 [TBL] [Abstract][Full Text] [Related]
14. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas. Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW Cells; 2023 Nov; 12(21):. PubMed ID: 37947652 [TBL] [Abstract][Full Text] [Related]
15. [Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma]. Drugeon C; Charlat I; Boulinguez S; Viraben R Ann Dermatol Venereol; 2007; 134(8-9):639-43. PubMed ID: 17925686 [TBL] [Abstract][Full Text] [Related]
16. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Lalloyer F; Fiévet C; Lestavel S; Torpier G; van der Veen J; Touche V; Bultel S; Yous S; Kuipers F; Paumelle R; Fruchart JC; Staels B; Tailleux A Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2731-7. PubMed ID: 17008586 [TBL] [Abstract][Full Text] [Related]
17. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Rigas JR; Dragnev KH Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250 [TBL] [Abstract][Full Text] [Related]
18. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650 [TBL] [Abstract][Full Text] [Related]
19. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Yen WC; Lamph WW Mol Cancer Ther; 2005 May; 4(5):824-34. PubMed ID: 15897247 [TBL] [Abstract][Full Text] [Related]
20. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Moerland JA; Zhang D; Reich LA; Carapellucci S; Lockwood B; Leal AS; Krieger-Burke T; Aleiwi B; Ellsworth E; Liby KT Sci Rep; 2020 Dec; 10(1):22244. PubMed ID: 33335263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]